FTC: Hikma Must Give Up 3 Generics For Roxane
This article was originally published in Scrip
Executive Summary
The Federal Trade Commission (FTC) told Hikma Pharmaceuticals PLC it had to sell two generic drugs and give up the rights to a third to settle charges the firm's proposed $2bn acquisition of Boehringer Ingelheim GmbH unit Roxane Laboratories Inc. is anticompetitive.
You may also be interested in...
Hikma Hit By Approval Delays, But Advair Diskus Generic Expected Next Year
Jordan's Hikma claims to be a more balanced generics company after the Roxane acquisition, and expects 2017 approval of an Advair Diskus generic, but delays in US generic approvals held back profits in the 2016 first half.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.